Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

Diuretic lowers heart failure risk

Chlorthalidone lowers the risk of new-onset hospitalised heart failure with preserved ejection fraction (HFPEF) and heart failure with reduced left ventricular ejection fraction (HFREF) compared with amlodipine and doxazosin, US researchers say.

An analysis of data from 900 participants in the ALLHAT trial showed chlorthalidone reduced the risk of HFPEF by 31% compared with amlodipine, 26% compared with lisinopril and 47% compared with doxazosin.

With HFREF, chlorthalidone was associated with a lower risk than amlodipine or doxazosin, but was similar to lisinopril.

Circulation 2008 10 November early online publication

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say